Company logo

DNLI - Denali Therapeutics Inc.

NASDAQ -> Healthcare -> Biotechnology
South San Francisco, United States
Type: Equity

DNLI price evolution
DNLI
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Current assets
Cash $127.11 $148.01 $131.97 $68.13
Short term investments $907.4 $961.25 $1059.01 $1220.32
Net receivables
Inventory
Total current assets $1064.14 $1142.88 $1224.06 $1325.16
Long term investments $7.91
Property, plant & equipment $71.64 $74.85 $67.24 $70.17
Goodwill & intangible assets
Total noncurrent assets $89.78 $93.89 $81.67 $84.18
Total investments $907.4 $969.15 $1059.01 $1220.32
Total assets $1153.92 $1236.78 $1305.73 $1409.34
Current liabilities
Accounts payable $9.48 $1.18 $8.52 $2.21
Deferred revenue
Short long term debt $7.01 $6.77 $6.54
Total current liabilities $77.98 $71.18 $69.36 $391.08
Long term debt $44.98 $46.89 $48.75 $50.55
Total noncurrent liabilities $44.98 $47.27 $49.55 $51.56
Total debt $44.98 $53.9 $55.52 $57.09
Total liabilities $122.96 $118.45 $118.91 $442.64
Shareholders' equity
Retained earnings -$1116.21 -$996.74 -$897.38 -$1080.77
Other shareholder equity $0.64 -$0.65 -$1.44 -$2.52
Total shareholder equity $1030.95 $1118.33 $1186.83 $966.71
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $127.11 $218.04 $293.48 $507.14
Short term investments $907.4 $1118.17 $571.93 $962.55
Net receivables $1.23 $5.7
Inventory
Total current assets $1064.14 $1372.32 $897.23 $1495.65
Long term investments $425.45 $32.7
Property, plant & equipment $71.64 $74.52 $69.61 $73.46
Goodwill & intangible assets
Total noncurrent assets $89.78 $87.92 $506.93 $108.63
Total investments $907.4 $1118.17 $997.38 $995.25
Total assets $1153.92 $1460.24 $1404.16 $1604.28
Current liabilities
Accounts payable $9.48 $2.79 $4.78 $1.07
Deferred revenue
Short long term debt
Total current liabilities $77.98 $363.92 $378.25 $71.7
Long term debt $44.98 $53.03 $58.55 $64.17
Total noncurrent liabilities $44.98 $53.89 $63.63 $382.05
Total debt $44.98 $53.03 $58.55 $64.17
Total liabilities $122.96 $417.81 $441.87 $453.75
Shareholders' equity
Retained earnings -$1116.21 -$970.99 -$645 -$354.42
Other shareholder equity $0.64 -$6.89 -$2.5 -$0.24
Total shareholder equity $1030.95 $1042.43 $962.29 $1150.53
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue $1.27 $294.12 $35.14
Cost of revenue
Gross Profit $1.27 $294.12 $35.14
Operating activities
Research & development $107.8 $89.74 $97.52 $128.82
Selling, general & administrative $24.77 $25.32 $26.12 $27.14
Total operating expenses $132.57 $115.06 $123.64 $155.96
Operating income -$132.57 -$113.8 $170.48 -$120.81
Income from continuing operations
EBIT -$119.44 -$99.35 $183.38 -$109.78
Income tax expense $0.03
Interest expense
Net income
Net income -$119.47 -$99.35 $183.38 -$109.78
Income (for common shares) -$119.47 -$99.35 $183.38 -$109.78
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $330.53 $108.46 $48.66 $335.66
Cost of revenue
Gross Profit $330.53 $108.46 $48.66 $335.66
Operating activities
Research & development $423.88 $358.73 $265.35 $212.62
Selling, general & administrative $103.35 $90.47 $79.06 $60.33
Total operating expenses $527.23 $449.21 $344.41 $272.94
Operating income -$196.7 -$340.74 -$295.75 $62.72
Income from continuing operations
EBIT -$145.19 -$325.97 -$291.16 $71.96
Income tax expense $0.03 $0.02 -$0.57 $0.82
Interest expense
Net income
Net income -$145.22 -$325.99 -$290.58 $71.14
Income (for common shares) -$145.22 -$325.99 -$290.58 $71.14
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income -$119.47 -$99.35 $183.38 -$109.78
Operating activities
Depreciation $2.18 $2.22 $2.29 $10.05
Business acquisitions & disposals
Stock-based compensation $25.99 $27.46 $26.57 $28.08
Total cash flows from operations -$98.66 -$87.36 -$113.17 -$58.8
Investing activities
Capital expenditures -$2.23 -$2.07 -$5.85 -$2.79
Investments $75.28 $102.98 $173.92 -$89.93
Total cash flows from investing $73.05 $100.91 $168.07 -$92.72
Financing activities
Dividends paid
Sale and purchase of stock $4.71 $2.49 $9.02 $1.6
Net borrowings
Total cash flows from financing $4.71 $2.49 $9.02 $1.6
Effect of exchange rate
Change in cash and equivalents -$20.91 $16.04 $63.92 -$149.91
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$145.22 -$325.99 -$290.58 $71.14
Operating activities
Depreciation $16.73 $10.38 $8.59 $8.53
Business acquisitions & disposals
Stock-based compensation $108.1 $99.85 $85.25 $50.35
Total cash flows from operations -$357.99 -$244.72 -$211.39 $416.15
Investing activities
Capital expenditures -$12.94 -$17.83 -$8.5 -$3.1
Investments $262.25 -$123.55 -$13.13 -$620.11
Total cash flows from investing $249.31 -$141.39 -$21.63 -$623.21
Financing activities
Dividends paid
Sale and purchase of stock $17.82 $310.67 $19.35 $634.75
Net borrowings
Total cash flows from financing $17.82 $310.67 $19.35 $634.75
Effect of exchange rate
Change in cash and equivalents -$90.86 -$75.43 -$213.67 $427.69
Fundamentals
Market cap $2.87B
Enterprise value $2.79B
Shares outstanding 138.20M
Revenue $330.53M
EBITDA -$128.47M
EBIT -$145.19M
Net Income -$145.22M
Revenue Q/Q -100.00%
Revenue Y/Y 204.74%
P/E ratio -19.76
EV/Sales 8.44
EV/EBITDA -21.70
EV/EBIT -19.20
P/S ratio 8.68
P/B ratio 2.79
Book/Share 7.46
Cash/Share 0.92
EPS -$1.05
ROA -11.38%
ROE -13.50%
Debt/Equity 0.12
Net debt/EBITDA 0.03
Current ratio 13.65
Quick ratio 13.65